2022
DOI: 10.1371/journal.pone.0270232
|View full text |Cite
|
Sign up to set email alerts
|

A systematic review and meta-analysis of preanalytical factors and methodological differences influencing the measurement of circulating vascular endothelial growth factor

Abstract: Background Intraocular treatment with antibodies targeting vascular endothelial growth factor (anti-VEGF) inhibits pathological vessel growth in adults and preterm infants. Recently, concerns regarding the impact of anti-VEGF treatment on systemic VEGF levels in preterm infants have been raised. Earlier studies suggest that preanalytical and methodological parameters impact analytical VEGF concentrations, but we have not found a comprehensive systematic review covering preanalytical procedures and methods for … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 94 publications
0
1
0
Order By: Relevance
“…A cross-sectional study of 21 healthy subjects and 64 patients with type 1 diabetes determined VEGF levels in plasma collected in both citrate and PECT (a medium that inactivates platelets) found that higher levels of VEGF in citrate plasma samples of diabetic patients do not represent the real situation in vivo but mainly originate from higher artificial ex vivo release from platelets (38). A recent meta-analysis showed that out of the different plasma types, using EDTA as an anticoagulant obtained the highest concentration of VEGF, followed by heparin and citrate, while CTAD reported the lowest content of VEGF (39). In addition, kits from different manufacturers bring different methods for the measurement of VEGF, and other factors, including batch, sensitivity and detection range, all contribute to the study of heterogeneity.…”
Section: Discussionmentioning
confidence: 99%
“…A cross-sectional study of 21 healthy subjects and 64 patients with type 1 diabetes determined VEGF levels in plasma collected in both citrate and PECT (a medium that inactivates platelets) found that higher levels of VEGF in citrate plasma samples of diabetic patients do not represent the real situation in vivo but mainly originate from higher artificial ex vivo release from platelets (38). A recent meta-analysis showed that out of the different plasma types, using EDTA as an anticoagulant obtained the highest concentration of VEGF, followed by heparin and citrate, while CTAD reported the lowest content of VEGF (39). In addition, kits from different manufacturers bring different methods for the measurement of VEGF, and other factors, including batch, sensitivity and detection range, all contribute to the study of heterogeneity.…”
Section: Discussionmentioning
confidence: 99%